Boehringer Ingelheim Initiates Long-term Study of Nerandomilast in Pulmonary Fibrosis Patients
A follow-up study is underway to evaluate the long-term tolerance and efficacy of nerandomilast in patients with pulmonary fibrosis.
Asset / Drug
Drug and asset intelligence for Boehringer with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.